Navigation Links
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
Date:12/7/2009

TAIPEI, Taiwan, Dec. 7 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

The clinical data of Phase 1 study will be presented. In this randomized, double-blind, placebo-controlled, sequential ascending single intravenous dose study, TG-0054 exhibited excellent and favorable safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) profile. A maximally tolerated dose (MTD) was established. Good tolerability was observed. PK parameters showed dose proportionality over the dose range studied. PD results showed potent, dose-dependent mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells into peripheral blood circulation.

The preclinical data will be reported on in vitro assays and in vivo studies in mouse models. TG-0054 demonstrated potent and selective antagonistic activities against CXCR4 in vitro. Significant mobilization of CD34+ hematopoietic stem cells and CD133+ endothelial progenitor cells was observed when TG-0054 was used alone or combined with G-CSF in preclinical models.

The preclinical and Phase I results support further clinical investigation. The Phase 2 study entitled "A Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients with Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease" will begin to enroll patients in December, 2009.

    ASH 2009 Meeting Presentation:

    Clinical
    Oral presentation: TG-0054, a Novel and Potent Stem Cell Mobilizer,
                       Displays Excellent PK/PD and Safety Profile in Phase 1
                       Trial
    Tuesday, December 8, 2009: 7:30 AM-9:00 AM

    Preclinical
    Poster: Rapid Mobilization of Murine Hematopoietic Stem and Progenitor
            Cells with TG-0054, a Novel CXCR4 Antagonist (Poster Board
            number: III-479)
    Monday, December 7, 2009: 6:00 PM-8:00 PM

About TaiGen Biotechnology

TaiGen Biotechnology ( http://www.taigenbiotech.com/ ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. In addition to TG-0054, Nemonoxacin, a novel broad-spectrum non-fluorinated quinolone with anti-MRSA activity and in-licensed from P&G Pharmaceuticals, achieved non-inferiority in clinical cure rate and safety profile compared with Levofloxacin in its Phase II CAP trial. The company has completed a second phase II study in diabetic foot infection to demonstrate Nemonoxacin's anti-MRSA activity with once-a-day oral dosing. TaiGen is seeking Nemonoxacin licensees for the US, EU and Japan markets. TaiGen also has HCV protease inhibitors in advanced preclinical programs to treat chronic hepatitis C infection.

    TaiGen Contact

     Dr. John Jin, VP Global Business Development
     Tel:   +886-2-2790-1861
     Email: johnjin@taigenbiotech.com.tw

SOURCE TaiGen Biotechnology Co., Ltd.


'/>"/>
SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
10. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  The Senior Care Pharmacy Coalition (SCPC) today ... Jason Chaffetz (R-UT) and Ranking Member ... , "Developments in the Prescription Drug Market," to ... about abusive pharmacy benefit manager (PBM) pricing practices. ... Member Elijah Cummings (D-MD) are diligent, serious lawmakers ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is ... in the field of Pharmaceuticals. Montoya is the Regulatory ... Manufacturing and ... Becton Dickinson provides healthcare institutions, clinical laboratories ... throughout fifty countries across the globe. ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS ... Designed to provide the most effective tattoo removal today, Dr. Bentkover is the only ... Developed by Cynosure, the PicoSure has been approved by the Food and Drug Administration ...
(Date:2/5/2016)... ... 05, 2016 , ... Colorize is a web theme package created ... next using Colorize's dynamic moving camera. Colorize is perfect for personal and web related ... environment with 1 to 5 focus points per scene, stage floor scene presets that ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, ... an illness. Migraines are a severe form of a headache and often are accompanied ... the pain on their worst enemy, the feeling can last for many hours and ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) announced ... in New York City on Thursday, January 21, 2016. Kingsley R. Chin, ... alumnus of the varsity Columbia soccer program) spoke at the event, offering professional ...
Breaking Medicine News(10 mins):